Emergent BioSolutions Inc. (EBS)
NYSE
Closed
Oct 8, 2026
Day's Range
6.7952 wk Range
4.36Overview - EBS - Emergent BioSolutions Inc.
Key Statistics
Valuation
Enterprise Value
773.06M
P/E (Trailing)
‪8.59‬
P/E (Forward)
‪6.04‬
PEG Ratio
‪0.0057‬
Price / Sales (TTM)
‪0.42‬
Price / Book
‪0.95‬
EV / EBITDA
‪3.29‬
Profitability
Gross Margin
‪57.18%‬
Profit Margin
‪-22.95%‬
Operating Margin
‪28.34%‬
Return on Assets
‪6.93%‬
Return on Equity
‪-40.29%‬
Ownership
Shares Outstanding
51.30M
Float
49.06M
Short % of Shares Outstanding
‪19.38%‬
Held by Insiders
‪4.25%‬
Held by Institutions
‪90.59%‬
Price stats
Beta
‪2.33‬
50-Day Avg
‪6.15‬
200-Day Avg
‪8.63‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Average price target
‪$ 11.00‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - EBS - Emergent BioSolutions Inc.
Peers - EBS - Emergent BioSolutions Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NYSE.
Profile Summary - EBS - Emergent BioSolutions Inc.
About
Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats. Its current business centers on medical countermeasures and specialty products, including public health protection tools used by government…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
